Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETX-407
- Development stage
- Preclinical
- Lead developer
- Tangram Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ETX-407 (also known as TGM-407) is a preclinical RNA interference (RNAi) therapeutic candidate being developed by Tangram Therapeutics (formerly e-therapeutics) for the treatment of dry age-related macular degeneration (AMD). The drug is part of the company's GalOmic platform, which utilizes N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) to achieve targeted gene silencing in hepatocytes. ETX-407 is designed to target a novel, undisclosed gene identified through computational discovery that is implicated in the progression of dry AMD. By modulating the expression of this target in the liver, the therapy aims to address systemic factors contributing to retinal degeneration.
- Other names
- TGM-407TGM407TGM 407
Beyond the preview
Go deeper on ETX-407.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETX-407.